Observational Study of a Novel Peri Infusion Regimen on the Infusion Associated Reactions With Alemtuzumab Infusion in Patients With Multiple Sclerosis in a Canadian Clinical Setting.
What it found
We found no results in the registry or in papers.
This trial finished 5 years ago. We found no results in the registry or in any paper that cites it.
What was tested
Treatment tested
- Alemtuzumab
CAMPATH-1 antigen inhibitor
What it measured
Main measures
Number and type of adverse events in Novel versus standard infusion protocol
2016-2020
Disability progressionSafety
Who could take part
MS (type not specified) · 18 to 65
Inclusion Criteria: Patient s treated with Alemtuzumab as per canadian label - Exclusion Criteria: Contraindication to Alemtuzumab -
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
To evaluate a Novel infusion protocol in MS patients treated with Alemtuzumab
Papers
Loading reviews and guidelines…
Related trials
- TDM-MS
Phase 4 · Status unknown
No result found
- CLADRI_NET
Phase 4 · Withdrawn
Stopped early
- STATURE
Status unknown
No result found
- Physical and Cognitive Performance During the Two First Y…
Completed
Result in a paper, not read yet
- ProgramMS
Status unknown
Result in a paper, not read yet
- LEMTRADA Pregnancy Registry in Multiple Sclerosis
Completed
No result found
History
Started
May 2016
Main results due
Dec 2020
Finished
Feb 2021
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error